From the editor--drug companies under investigation.
Thomas
Sandra P
SP
D000588:Amines / Q000009:adverse effects*; D000927:Anticonvulsants / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects*; D004345:Drug Industry / Q000592:standards*; D004346:Drug Information Services / Q000592:standards; D005607:Fraud; D000077206:Gabapentin; D006801:Humans; D024802:Nurse's Role; D017374:Paroxetine / Q000009:adverse effects*; D010344:Patient Advocacy; D011568:Psychiatric Nursing / Q000458:organization & administration; D013405:Suicide / Q000706:statistics & numerical data; D014481:United States; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects*
D000588:Amines; D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D003509:Cyclohexanecarboxylic Acids; D017374:Paroxetine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin